Literature DB >> 16207133

Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry.

Michael Vogeser1, Xaver Schiel, Ute Spöhrer.   

Abstract

A convenient liquid chromatography-tandem mass spectrometry method for the quantification of the triazole antifungal agent voriconazole in plasma samples is described. Fenbuconazole is used as an internal standard. After protein precipitation, automated solid-phase extraction is applied. Electrospray ionization in the positive mode is used and the following mass transitions are recorded: voriconazole, 350-->127; and fenbuconazol, 337-->125. The analytical run time is 4 min. The response was linear from 78 to 5000 microg/L. The total coefficient of variation (n=16) was 12.6% for a low-concentration pool (143 microg/L), 4.7% for a medium-concentration pool (419 microg/L), and 5.0% for a high-concentration pool (4304 microg/L). The method is proposed for future investigations that should be performed to test the hypothesis that therapeutic drug monitoring of voriconazole is clinically useful.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207133     DOI: 10.1515/CCLM.2005.124

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation.

Authors:  Shirley Qiong Yan; Brian Seyboth; Rachel Kobos; Anne Eaton; Susan K Seo; Nina Cohen
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-15       Impact factor: 3.164

3.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

4.  Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.

Authors:  I Fan Kuo; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-11

5.  Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Authors:  David J Epstein; Susan K Seo; Yao-Ting Huang; Jay H Park; Virginia M Klimek; Ellin Berman; Martin S Tallman; Mark G Frattini; Genovefa A Papanicolaou
Journal:  J Infect       Date:  2018-05-07       Impact factor: 6.072

6.  Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy.

Authors:  Lalit Saini; Jack T Seki; Deepali Kumar; Eshetu G Atenafu; David Ec Cole; Betty Yl Wong; Andrea Božović; Joseph M Brandwein
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471

Review 7.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

8.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yukihiro Hamada; Issei Tokimatsu; Hiroshige Mikamo; Masao Kimura; Masafumi Seki; Shunji Takakura; Norio Ohmagari; Yoshiko Takahashi; Kei Kasahara; Kazuaki Matsumoto; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Takahiro Mochizuki; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura; Yoshio Takesue
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.